Osiris Therapeutics, Inc. (Pink Sheets: OSIR), a leading regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announced today that a new peer reviewed manuscript entitled “Placental Membranes for Management of Refractory Cutaneous Sinus Tracts of Surgical Origin: A Pilot Study” has been published in The Journal of the American College of Clinical Wound Specialists and is available online.
The Richard A. Henson Foundation, Inc. today reaffirmed its commitment to Salisbury University, announcing a $2.5 million gift for SU’s Richard A. Henson School of Science and Technology.
A pioneer in the commuter aviation industry, Henson endowed the school bearing his name with another multi-million-dollar donation in 1987. This latest marks the 30th anniversary of that initial commitment.
The credibility of stem cell research is at risk because of charlatans and dodgy clinics peddling unproven cures for diseases, according to a group of eminent scientists in the field.
Circulomics, a Baltimore, MD-based biotechnology startup, received two SBIR grants totaling over $1.7M.
The company will use the funds to develop new applications of its Nanobind DNA/RNA extraction technology.
[THE INVESTOR] In the age of “digital health care,” high-tech wearables, cutting-edge medical devices and integrated apps combined with major breakthroughs in data computing and analytics capabilities are set to pave new frontiers in the health care sector.
A new academic enterprise, born of a partnership between the University of Washington and China’s Tsinghua University — and seeded with $40 million in funding from Microsoft — welcomed its first class of master’s students this fall.
Gene therapy is at the forefront of preventative and therapeutic technologies targeting diseases that have no other cures. Join us as two leading gene therapy experts, Drs. Karen Kozarsky and Lynne Fahey McGrath, discuss different types of gene therapy, advanced programs, and the associated unique regulatory challenges.
Rhythm Pharmaceuticals $RYTM became the latest biotech to tap into a buoyant market, raising $120 million in an IPO that went over the range at $17 a share. And they can add substantially to that if the underwriters pick up another million shares on the table.
We know from following the Rise of the Rest that D.C. isn’t in the top three for metros venture capital investments, but a new study said it makes the top 10.
The Center for Innovative Technology (CIT) announced today the Commonwealth Research Commercialization Fund (CRCF) Request for Proposals (RFP) for FY2018.
